Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

T. Herzog · SciRah

Researcher profile · Semantic Scholar

T. Herzog

Share profile

T. Herzog — researcher profile on SciRah

h-index: 71
Works: 496
Citations: 18K

Most-cited papers

Dostarlimab for Primary Advanced or Recurrent Endometrial Cancer.
M. Mirza, D. Chase, B. Slomovitz, René dePont Christensen +27 more
2023New England Journal of Medicine685 citations Open access
Semantic Scholar
Overall Survival in Patients with Endometrial Cancer Treated with Dostarlimab plus Carboplatin-Paclitaxel in the Randomized ENGOT-EN6/GOG-3031/RUBY Trial.
M. Powell, L. Bjørge, L. Willmott, Z. Novak +27 more
2024Annals of Oncology132 citations Open access
Semantic Scholar
ATHENA (GOG-3020/ENGOT-ov45): a randomized, phase III trial to evaluate rucaparib as monotherapy (ATHENA–MONO) and rucaparib in combination with nivolumab (ATHENA–COMBO) as maintenance treatment following frontline platinum-based chemotherapy in ovarian cancer
B. Monk, R. Coleman, K. Fujiwara, M. Wilson +17 more
2021International Journal of Gynecological Cancer88 citations Open access
Semantic Scholar
Testing for homologous recombination repair or homologous recombination deficiency for poly (ADP-ribose) polymerase inhibitors: A current perspective.
T. Herzog, I. Vergote, L. Gomella, T. Milenkova +4 more
2022European Journal of Cancer47 citations Open access
Semantic Scholar
Safety and activity of anti-mesothelin antibody–drug conjugate anetumab ravtansine in combination with pegylated-liposomal doxorubicin in platinum-resistant ovarian cancer: multicenter, phase Ib dose escalation and expansion study
A. Santin, I. Vergote, A. González-Martín, K. Moore +16 more
2022International Journal of Gynecological Cancer39 citations Open access
Semantic Scholar
Gemogenovatucel-T (Vigil) immunotherapy demonstrates clinical benefit in homologous recombination proficient (HRP) ovarian cancer.
R. Rocconi, B. Monk, Adam Walter, T. Herzog +9 more
2021Gynecologic Oncology33 citations
Semantic Scholar
COVID‐19 pandemic and impact on cancer clinical trials: An academic medical center perspective
Michelle Marcum, N. Kurtzweil, C. Vollmer, Lisa Schmid +9 more
2020Cancer Medicine33 citations Open access
Semantic Scholar
A phase 3 randomized, open-label, multicenter trial for safety and efficacy of combined trabectedin and pegylated liposomal doxorubicin therapy for recurrent ovarian cancer.
B. Monk, T. Herzog, George C. Wang, Spyros Triantos +5 more
2020Gynecologic Oncology30 citations
Semantic Scholar
Single cell transcriptomic analysis of HPV16-infected epithelium identifies a keratinocyte subpopulation implicated in cancer
Mary C. Bedard, Tafadzwa Chihanga, A. Carlile, Robert Jackson +30 more
2023Nature Communications29 citations Open access
Semantic Scholar
Phase 1b study of AVB-500 in combination with paclitaxel or pegylated liposomal doxorubicin platinum-resistant recurrent ovarian cancer.
K. Fuh, M. Bookman, Joyce F. Liu, R. Coleman +7 more
2021Gynecologic Oncology29 citations Open access
Semantic Scholar
The Impact of Opportunistic Salpingectomy on Ovarian Cancer Mortality and Healthcare Costs: A Call For Universal Insurance Coverage.
R. Naumann, B. Hughes, Jubilee Brown, L. Drury +1 more
2021American Journal of Obstetrics and Gynecology26 citations
Semantic Scholar
State of the science: Contemporary front-line treatment of advanced ovarian cancer.
E. Hinchcliff, S. Westin, T. Herzog
2022Gynecologic Oncology25 citations Open access
Semantic Scholar
Proof of principle study of sequential combination atezolizumab and Vigil in relapsed ovarian cancer
R. Rocconi, E. E. Stevens, J. Bottsford-Miller, S. Ghamande +16 more
2021Cancer Gene Therapy21 citations
Semantic Scholar
Randomized phase II trial of farletuzumab plus chemotherapy versus placebo plus chemotherapy in low CA-125 platinum-sensitive ovarian cancer.
T. Herzog, S. Pignata, S. Ghamande, M. Rubio +20 more
2023Gynecologic Oncology20 citations
Semantic Scholar
Genomic profiling in low grade serous ovarian cancer: Identification of novel markers for disease diagnosis and therapy.
A. ElNaggar, D. Robins, Y. Baca, D. Arguello +11 more
2022Gynecologic Oncology20 citations
Semantic Scholar
Gemogenovatucel-T (Vigil) maintenance immunotherapy: 3-year survival benefit in homologous recombination proficient (HRP) ovarian cancer.
Adam Walter, R. Rocconi, B. Monk, T. Herzog +9 more
2021Gynecologic Oncology19 citations Open access
Semantic Scholar
The Genomic Landscape of Vulvar Squamous Cell Carcinoma
L. Corey, J. Wallbillich, Sharon Wu, A. Farrell +19 more
2023International Journal of Gynecological Pathology17 citations Open access
Semantic Scholar
ARTISTRY-7: Phase III trial of nemvaleukin alfa plus pembrolizumab vs chemotherapy for platinum-resistant ovarian cancer.
T. Herzog, J. Hays, J. Barlin, J. Buscema +18 more
2023Future Oncology16 citations Open access
Semantic Scholar
Assessment of immune biomarkers and establishing a triple negative phenotype in gynecologic cancers.
G. Contos, Y. Baca, J. Xiu, J. Brown +5 more
2021Gynecologic Oncology16 citations
Semantic Scholar
Diagnosing and staging epithelial ovarian cancer by serum glycoproteomic profiling
Chirag Dhar, P. Ramachandran, G. Xu, C. Pickering +15 more
2023British Journal of Cancer12 citations Open access
Semantic Scholar
Cardiac safety of trabectedin monotherapy or in combination with pegylated liposomal doxorubicin in patients with sarcomas and ovarian cancer
Robin L. Jones, T. Herzog, Shreyaskumar R. Patel, M. von Mehren +10 more
2021Cancer Medicine12 citations Open access
Semantic Scholar
Utilizing an interim futility analysis of the OVAL study (VB-111-701/GOG 3018) for potential reduction of risk: A phase III, double blind, randomized controlled trial of ofranergene obadenovec (VB-111) and weekly paclitaxel in patients with platinum resistant ovarian cancer.
R. Arend, B. Monk, T. Herzog, K. Moore +10 more
2021Gynecologic Oncology11 citations Open access
Semantic Scholar
COVID-19 and ovarian cancer: Exploring alternatives to intravenous (IV) therapies
B. Monk, R. Coleman, K. Moore, T. Herzog +5 more
2020Gynecologic Oncology11 citations Open access
Semantic Scholar
What proportion of patients with stage 3 ovarian cancer are potentially cured following intraperitoneal chemotherapy? Analysis of the long term (≥10 years) survivors in NRG/GOG randomized clinical trials of intraperitoneal and intravenous chemotherapy in stage III ovarian cancer
Omali Pitiyarachchi, M. Friedlander, J. Java, J. Chan +13 more
2022Gynecologic Oncology10 citations Open access
Semantic Scholar
ENTPD1/CD39 as a predictive marker of treatment response to gemogenovatucel-T as maintenance therapy in newly diagnosed ovarian cancer
R. Rocconi, L. Stanbery, M. Tang, L. Madeira da Silva +11 more
2022Communications Medicine10 citations Open access
Semantic Scholar
The importance of information, motivation, and behavioral skills (IMB): Healthcare provider perspectives on improving adherence to cervical cancer screening among at-risk women
A. Wells, V. Allen-Brown, Nadia Alam, Caroline Skulski +2 more
2021Public Health in Practice10 citations Open access
Semantic Scholar
UP-NEXT (GOG-3049/ENGOT-Ov71-NSGO-CTU): A study of upitifamab rilsodotin (UpRi), a NaPi2b-directed antibody drug conjugate (ADC), in platinum-sensitive recurrent ovarian cancer.
D. Richardson, P. Harter, D. O'Malley, A. González-Martín +6 more
2023Journal of Clinical Oncology9 citations
Semantic Scholar
The clinical and prognostic significance of pre-chemotherapy serum CA-125 in high-risk early stage ovarian cancer: An NRG/GOG ancillary study.
J. Chan, C. Tian, J. Kesterson, M. Richardson +15 more
2022Gynecologic Oncology9 citations Open access
Semantic Scholar
HER2 in uterine serous carcinoma: Testing platforms and implications for targeted therapy.
Tenley R. Klc, Sharon Wu, A. Wilhite, N. Jones +11 more
2021Journal of Clinical Oncology8 citations
Semantic Scholar
Predicted immunogenicity of CDK12 biallelic loss-of-function tumors varies across cancer types.
A. Elliott, Jian Zhang, Qing Zhang, J. Swensen +11 more
2021Journal of Molecular Diagnostics8 citations Open access
Semantic Scholar
Acute pulmonary complications in the setting of high risk gestational trophoblastic neoplasia and induction of chemotherapy
H. Khadraoui, T. Herzog, A. Jackson, C. Billingsley
2023Gynecologic Oncology Reports7 citations Open access
Semantic Scholar
A phase I combination study of vigil and atezolizumab in recurrent/refractory advanced-stage ovarian cancer: Efficacy assessment in BRCA1/2-wt patients.
R. Rocconi, E. E. Stevens, J. Bottsford-Miller, S. Ghamande +10 more
20207 citations
Semantic Scholar
527MO Rucaparib maintenance treatment in patients (pts) with newly diagnosed ovarian cancer (OC): Defining benefit according to disease risk subgroups within the phase 3 ATHENA–MONO study
K. Fujiwara, R. Kristeleit, S. Ghamande, M. Lim +16 more
2022Annals of Oncology6 citations Open access
Semantic Scholar
793TiP A phase III, randomized, open-label, multicenter study of sacituzumab tirumotecan (sac-TMT) monotherapy vs treatment of physician’s choice chemotherapy in patients with endometrial cancer who have received prior chemotherapy and immunotherapy: ENGOT-en23/GOG-3095/MK-2870-005
D. Lorusso, M. Mirza, J. Martin-Babau, A. Bologna +16 more
2024Annals of Oncology5 citations Open access
Semantic Scholar
Systematic mapping review of guidelines for BRCA1/2 genetic testing globally: investigating geographic and regional disparities in health equity for women and families at risk for hereditary ovarian cancer
B. Hughes, Kirsten Jorgensen, S. Cummings, D. Morah +3 more
2022International Journal of Gynecological Cancer5 citations Open access
Semantic Scholar
Integrating Precision Medicine into the Contemporary Management of Gynecologic Cancers
Juliet E. Wolford, Erin Ferrigni, Daniel J. Margul, T. Herzog
2022Current Oncology Reports5 citations
Semantic Scholar
Whole exome sequencing provides loss of heterozygosity (LoH) data comparable to that of whole genome sequencing (171)
E. Evans, Jhalak Dholakia, J. Abraham, Jian Zhang +5 more
2022Gynecologic Oncology5 citations
Semantic Scholar
The GOG partners: A program for industry sponsored clinical trials in gynecologic oncology within the GOG foundation.
B. Monk, R. Coleman, T. Herzog, K. Moore +8 more
2021Gynecologic Oncology5 citations Open access
Semantic Scholar
ARTISTRY-7: A phase 3, multicenter study of nemvaleukin alfa in combination with pembrolizumab versus chemotherapy in patients with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer (GOG-3063; ENGOT-OV68).
T. Herzog, J. Hays, J. Barlin, J. Buscema +16 more
2023Journal of Clinical Oncology4 citations Open access
Semantic Scholar
Practice changing cervical cancer clinical trials.
B. Pothuri, R. Eskander, L. Randall, D. O'Malley +6 more
2022Gynecologic Oncology4 citations
Semantic Scholar
The role of blinded independent radiologic review in ovarian cancer clinical trials: Discerning the value.
A. Loreen, C. Polen-De, B. Monk, A. Jackson +2 more
2021Gynecologic Oncology4 citations
Semantic Scholar
Maintenance vigil immunotherapy in newly diagnosed advanced ovarian cancer: Efficacy assessment of homologous recombination proficient (HRP) patients in the phase IIb VITAL trial.
R. Rocconi, S. Ghamande, M. Barve, E. E. Stevens +9 more
20214 citations
Semantic Scholar
Early diagnosis and treatment challenges of endodermal sinus tumors: A case report
Madeline F. Perry, A. Jackson, T. Herzog, C. Billingsley
2020Case Reports in Women's Health4 citations Open access
Semantic Scholar
Randomized controlled phase III trial of weekly paclitaxel ± ofranergene obadenovec (VB-111) for platinum-resistant ovarian cancer (OVAL Study/GOG 3018).
R. Arend, B. Monk, R. Shapira-Frommer, A. Secord +16 more
2023Journal of Clinical Oncology3 citations
Semantic Scholar
The Genomic Landscape of Vulvovaginal Squamous Cell Carcinoma (048)
J. Wallbillich, Sharon Wu, L. Corey, A. Farrell +16 more
2022Gynecologic Oncology3 citations
Semantic Scholar
Genomic alterations, molecularly targeted therapy and race: Real world data from the Endometrial Cancer Molecularly Targeted Therapy Consortium (LBA 8)
A. Secord, B. Pothuri, F. Backes, P. Thaker +21 more
2022Gynecologic Oncology3 citations
Semantic Scholar
Comparison of incidence of hypersensitivity reactions of paclitaxel infusions with titrated versus non-titrated infusions
Erin Ferrigni, Lisa Grate, T. Herzog, C. Billingsley +1 more
2021Gynecologic Oncology3 citations
Semantic Scholar
Too much skin in the game? A paradigm shift in our understanding of vulvar and vaginal melanomas as distinct tumor types compared with cutaneous melanomas
A. Wilhite, Sharon Wu, J. Xiu, W. Korn +7 more
2021Gynecologic Oncology3 citations
Semantic Scholar
Selecting new upfront regimens for advanced ovarian cancer with biomarker guidance.
J. Chan, Su-Ying Liang, D. Kapp, Joshua E. Chan +4 more
2020Gynecologic Oncology3 citations
Semantic Scholar
Analysis of concordance between microsatellite instability by next generation sequencing (NGS-MSI) and mismatch repair deficiency by immunohistochemistry (IHC-MMR) in >28,000 colorectal tumors.
R. Ali-Fehmi, M. Oberley, H. Kraus, T. Herzog +10 more
2023Journal of Clinical Oncology2 citations
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

B. Monk×26
Invite
B. Monk — researcher profile on SciRah
R. Coleman×16
Invite
R. Coleman — researcher profile on SciRah
K. Moore×9
Invite
K. Moore — researcher profile on SciRah
D. O'Malley×8
Invite
D. O'Malley — researcher profile on SciRah

×7

Invite

R. Rocconi — researcher profile on SciRah

B. Slomovitz×6

Invite

B. Slomovitz — researcher profile on SciRah

Invite

L. Copeland — researcher profile on SciRah

Invite

L. Manning — researcher profile on SciRah

Invite

E. Bognar — researcher profile on SciRah

J. Nemunaitis×6

Invite

J. Nemunaitis — researcher profile on SciRah

Invite

B. Pothuri — researcher profile on SciRah

G. Wallraven×5

Invite

G. Wallraven — researcher profile on SciRah